CXA-101/ tazobactam and metronidazole + meropenem plus saline placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Complicated Intra-abdominal Infection
Conditions
Complicated Intra-abdominal Infection
Trial Timeline
Jun 25, 2010 → Mar 25, 2011
NCT ID
NCT01147640About CXA-101/ tazobactam and metronidazole + meropenem plus saline placebo
CXA-101/ tazobactam and metronidazole + meropenem plus saline placebo is a phase 2 stage product being developed by Merck for Complicated Intra-abdominal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01147640. Target conditions include Complicated Intra-abdominal Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01147640 | Phase 2 | Completed |
Competing Products
20 competing products in Complicated Intra-abdominal Infection